E2F4 regulatory program predicts patient survival prognosis in breast cancer.

ABSTRACT:

Introduction

Genetic and molecular signatures have been incorporated into cancer prognosis prediction and treatment decisions with good success over the past decade. Clinically, these signatures are usually used in early-stage cancers to evaluate whether they require adjuvant therapy following surgical resection. A molecular signature that is prognostic across more clinical contexts would be a useful addition to current signatures.

Methods

We defined a signature for the ubiquitous tissue factor, E2F4, based on its shared target genes in multiple tissues. These target genes were identified by chromatin immunoprecipitation sequencing (ChIP-seq) experiments using a probabilistic method. We then computationally calculated the regulatory activity score (RAS) of E2F4 in cancer tis

SUBMITTER: Khaleel SS 

PROVIDER: S-EPMC4303196 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature